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Abstract
Introduction: Radioiodine treatment (RT) of benign thyroid diseases is a well-known, safe, and effective treatment. In a group of patients
after RT, who remained in long-term follow-up, sporadic cases of malignant thyroid lesions occurred. The aim of the study was to estimate
how often it happened despite the exclusion of malignancy before RT.
Material and method: A group of 4314 patients (7438 person-years) underwent RT and subsequently were followed-up for 1–8 years
(mean 20.69 months). Apart from thyroid function estimation, if needed, fine needle aspiration biopsy (FNAB) of the thyroid or neck focal
lesions was performed based on ultrasonographic or clinical examination. Patients with pathological FNAB were analyzed and histo-
pathologically verified.
Results: In 12 out of 4314 cases (0.27%) suspicious FNAB results were found. Suspicious thyroid lesion results were found in 9 patients
(8 F, 1 M), aged 46–73 (average 56 years) followed up for 3–57 months after RT: papillary cancer in two patients, Hürthle cell tumour in one
patient, and suspicious cells in two patients (with benign lesions on postoperative histopathology). Two patients refused surgery (a suspi-
cion of papillary cancer in one case and suspicious cells in FNAB in the second case). A follicular tumour in FNAB was suspected in two
cases (no data about the first, and the second with lung cancer was not operable). In the remaining 3 cases FNAB revealed lymph node
metastases due to other cancers.
Conclusions: Malignant thyroid lesions in patients after RT due to benign thyroid diseases are seldom detected. However, periodical
clinical and ultrasonographic evaluation is recommended. (Pol J Endocrinol 2010; 61 (5): 454–457)
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Streszczenie
Wstęp: Leczenie radiojodem (RT, radioiodine treatment) chorób łagodnych tarczycy jest uznaną, bezpieczną i skuteczną metodą. W grupie
chorych po RT, pozostających pod wieloletnią obserwacją autorów pracy, czasami zdarzały się przypadki zmian nowotworowych
w tarczycy. Postanowiono ocenić jak często, mimo wykluczenia zmian złośliwych w tarczycy przed leczeniem, może się to zdarzyć
w dłuższym okresie obserwacji.
Materiał i metody: Grupa 4314 chorych (7438 osobolat) po RT pozostawała następnie pod obserwacją od 1–8 lat (śr. 20,69 miesięcy).
W trakcie badań kontrolnych, oprócz oceny czynności tarczycy, wykonywano między innymi biopsję aspiracyjną cienkoigłową (BAC)
zmian ogniskowych w tarczycy lub zmian na szyi, do której kwalifikowano ultrasonograficznie lub klinicznie (pojawienie się zmiany
palpacyjnej). Pacjentów z nieprawidłowym BAC analizowano i weryfikowano histopatologicznie.
Wyniki: U 12 z 4314 (0,27%) chorych stwierdzono w BAC zmiany podejrzane. Zmiany w tarczycy znaleziono u 9 osób (8 K, 1 M) w wieku
46–73 lat (śr. wieku 56 lat), 3–57 miesięcy po RT. Raka brodawkowatego stwierdzono u dwóch osób, guz z komórek Hürthle’a u jednej
osoby, cytologicznie podejrzane komórki u dwóch osób (histopatologicznie zmiany łagodne). Dwie chore nie zgodziły się na leczenie
operacyjne: jedna z podejrzeniem raka brodawkowatego, a druga z komórkami cytologicznie podejrzanymi w BAC. Guzek pęcherzyko-
wy był podejrzany u 2 chorych: o jednej z nich nie ma danych, drugi chory został zdyskwalifikowany do leczenia operacyjnego tarczycy
z powodu współistniejącego rozpoznania raka płuca. U pozostałych 3 osób stwierdzono zmiany przerzutowe w okolicznych węzłach
chłonnych z powodu innych nowotworów.
Wnioski: Zmiany nowotworowe w tarczycy u pacjentów po RT z powodu zmian łagodnych zdarzają się sporadycznie, ale wskazana jest
okresowa ocena kliniczna i ultrasonograficzna tych chorych. (Endokrynol Pol 2010; 61 (5): 454–457)
Słowa kluczowe: nadczynność tarczycy, nowotwory tarczycy, choroba Gravesa-Basedowa, wole guzkowe, leczenie 131I
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Introduction
Benign thyroid diseases constitute one of the oldest in-
dications for radionuclide therapy. For more than
60 years 131I has been applied for diffuse and nodular
hyperthyroidism. It may also be used for large non-toxic
goitres if patients are not eligible for surgery. Its effica-
cy is beyond discussion and many studies have shown
the safety of such therapy [1–5]. However, prior to qual-
ification for radioiodine therapy (RT), patients should
be carefully screened for possible malignancy. Accord-
ing to generally accepted practice, one year follow-up
at a nuclear medicine department is recommended [6,
7]. Some papers concerning long-term cancer risk in
hyperthyroid patients treated with radioiodine have
been published recently [8, 9]. In a group of patients
after RT, who remained in our long-term follow-up,
sporadic cases of malignant thyroid lesions occurred.
The aim of the study was to estimate how often it can
happen in long-term follow-up despite the exclusion
of malignancy before the RT.
Material and methods
A group of 4314 patients underwent RT in the years
2000–2008 due to TNG, GD, or in a few cases enlarged
non-toxic goiter. The diagnosis of the type of hyper-
thyroidism was based on clinical data, ultrasonography
examination, radioiodine uptake, thyroid scintigraphy,
and thyroid function laboratory measurements. In the
whole group, thyroid malignancy was excluded and the
same means of therapeutic dose calculation based on
the Marinelli formula was performed.
The present analysis covers 7438 person-years with
a mean follow-up time of 20.69 months (range 3–84
months) after commencing RT. Patients were supposed
to be at obligatory follow-up for one year after the treat-
ment at a nuclear medicine out-patient clinic, but many
of them continued for up to 8 years.
During routine checking procedure, as well as thy-
roid function estimation, a FNAB of the focal lesions in
the thyroid or in the neck was performed based on ul-
trasonography or clinical examination (if a new palpa-
ble nodule occurred). Patients with pathological FNAB
were analyzed and histopathologically verified.
Results
In 12 out of 4314 cases (0.27%), suspicious lesions were
found in FNAB. Lesions in the thyroid were found in
9 patients (8 F, 1 M), aged 46–73 (average 56 years)
and followed-up for 3–57 months after RT. Detailed in-
formation about FNAB-positive patients is shown in
Table I.
Table I. Characterics of FNAB-positive patients
Tabela I. Charakterystyka chorych z dodatnim wynikiem biopsji aspiracyjnej cienkoiglowej
Pt Age Diagnose Time since elapsed AD (Gy) FNAB Histopathology
(yrs)/sex  RT(months)
1 73/F TNG 39 250 Suspicious cells* Papillary cancer
2 46/F GB 57 (I dose) 150 Papillary cancer* Papillary cancer
48 (II dose) 250
3 48/F GB 28 ND Suspicion of Hürthle Hürthle cell adenoma
cell tumour**
4 63/F TNG 3 250 Atypical polymorphic cells, Normal
histopathology required***
5 48/F TNG 4 300 Follicular tumour? Normal
Follicular cancer?
Hyperplastic nodule?*
6 55/F TNG 33 150 Papillary cancer or lesion Refused to
after treatment*  be operated
7 45/F TNG 26 (I dose) 250 Suspicious cells* Refused
46/F 38 (II dose) 250 to be operated
8 53F TNG 35 200 Follicular tumour ND
9 72M GB 26 200 Follicular tumour Advanced lung cancer
10 54M GB 82 (I dose) ND Squamous cell cancer*** Not operated
61M 2 (II dose) 150  (lung cancer)
11 66M TNG 72 ND Metastases from Not operated
squamous cell cancer***
12 70M GB 25 200 Non microcellular cancer*** Not operated (lung cancer)
Pt — patient number, F — female, M — male, Gy — Grey; Indication for FNAB of the lesion for the biopsy: *Enlargement of the lesion in sonography
examination; **New lesion in sonography examination; ***Palpable lymph node
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Papillary cancer was confirmed histopathologically
in two cases: in patient number 1 with a toxic nodular
goiter (TNG), 39 months after RT, and in patient num-
ber 2 with Graves-Basedow (GB) disease, 48 months
after the second course of RT (the first dose was admin-
istered nine months earlier). In patient 1 with TNG, the
absorbed dose for the whole thyroid volume was 250 Gy.
In patient 2 with GB, the cumulated absorbed dose was
400 Gy. The dose was 150 Gy at the first approach, fol-
lowed by 250 Gy in 9 monthly intervals due to the per-
sistence of hyperthyroidism.
In the third patient with GB (patient 3) 28 months
after RT a Hürthle cell tumour was diagnosed and post-
operative histopathology showed Hürthle cell ade-
noma.
 In that particular case, we have no data about the
absorbed dose. In patients 4 and 5 with TNG, four and
three months after RT, FNAB revealed suspicious cells
and the histopathology examination showed benign
lesions.
Patient 6 with TNG, who received 150 Gy, had
a suspicion of papillary cancer 33 months after RT. Pa-
tient 7 with diagnosis of TNG had suspicious cells in
FNAB performed 38 months after RT with 250 Gy as
the thyroid absorbed dose. Patient 6 and patient 7 did
not agree to surgery and until now are in good health.
Follicular tumours were suspected in patients 8 and
9. There is no data about the postoperative histopathol-
ogy of patient 8 with TNG and FNAB performed
35 months after RT. Patient 9 with GB and FNAB,
26 months after RT, was not qualified for surgery due
to diagnosis of lung cancer. The absorbed dose in the
last two cases was 200 Gy each.
In the remaining 3 cases, metastases in neck lymph
nodes were found due to other cancers (squamous cell
carcinoma in patients 10 and 11 and from an unknown
cancer in patient 12). Patient 10 received two courses of
RT. An enlarged lymph node was found 82 months af-
ter the first course (2 months after the second I131 ad-
ministration). Patients 11 and 12 had enlarged nodes
diagnosed 72 and 25 months after RT, respectively.
Discussion
The main target of radionuclide treatment in benign
thyroid disease is both immunogenic (GD) and non-
immunogenic hyperthyroidism (TNG). Large non-tox-
ic goitre may be taken into consideration as well, espe-
cially if contraindicated for surgery. In the majority of
papers, the thyroid function impairment (hypothyroid-
ism less often than hyperthyroidism) is regarded as
a factor which makes thyroid cancer less possible. How-
ever, this assumption is not correct if no autonomous
nodule is stated.
There is no strict recommendation concerning the
protocol of imaging and follow-up for patients previ-
ously treated [7, 10]. Many reports in literature point
out the safety of RT [1–5, 11]. However, a nuclear med-
icine practitioner, when treating a hyperthyroid patient
with radioiodine, has to keep in mind the possible oc-
currence of malignancy prior to the treatment and
should be concerned with the proper follow-up after
the end of therapy [6]. The authors of this paper have
also described their own experiences in proper selec-
tion of patients for RT [12, 13]. Now we have attempted
to discover how often thyroid gland cancer occurs de-
spite the appropriate preselection before RT at our out-
patient clinic.
The majority of the FNABS performed were done
more than 24 months after the treatment. Patients 4 and
5 (interval 3 and 4 months after RT, respectively) proba-
bly showed false positive FNAB results caused by the
radionuclide treatment itself. The postoperative histopa-
thology in both cases was normal. The absorbed dose in
all cases was applied according to the protocols [14–17].
The absorbed doses proposed for GB and TNG could
be as high as 300 Gy if whole thyroid volume is taken
into account. In fact, the risk of thyroid cancer is lower
at thyroid ablative doses.
Regardless of the fact that RT is considered as
a generally safe procedure [2], some publications point
out increased cancer incidence among hyperthyroid pa-
tients in comparison to matched control groups. Metso
et al. showed an increased stomach, kidney, and breast
cancer risk in these patients [8, 9]. They found that can-
cers occurred 5 years from RT. Similar conclusions were
drawn 16 years earlier by Holm et al. In their study, sig-
nificantly elevated risks were discovered for cancers of
the stomach, kidney, and brain among 10-year survivors
[18]. As to the mortality increase, it is underlined in Lu-
cignani’s comment on Metso’s findings: hyperthyroid-
ism is a serious condition, so increased mortality can be
tailored with hyperthyroidism per se [9].
Indeed, the risk of death due to endocrine and met-
abolic disorders, as well as circulatory diseases, was sig-
nificantly greater in 131I-treated patients in relation to
the general population in a publication presented by
Franklyn [19]. In this paper, there was no explanation
regarding the underlying endocrine disorders treated
by RT, and no data on the absorbed doses of 131I that
were given. However, the reader can find the range of
administered activity of radioiodine (45% of the whole
cohort received more than 480 MBq).
Contrary to previous conclusions, Ron et al. state in
their paper that ten years after 131I treatment for adult
hyperthyroidism no risk of an increase in total cancer
mortality was found. Among patients with GB, thyroid
cancer mortality was increased, but not significantly,
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after five or more years of follow-up. There was a rela-
tionship between the number of 131I treatments, dose, and
overall cancer mortality. Among patients with toxic nod-
ular goiter, there was no relationship between the 131I
activity given and cancer mortality (but the number of
cases was not large, and confidence intervals were wide)
[20]. Hermus noticed that patients treated with radioio-
dine due to toxic nodular goiter “have an increased risk
of thyroid carcinoma, because the paranodular tissue may
receive sub-lethal mutagenic doses of radiation”. But in
his conclusion, the author underlines that “in a large fol-
low-up study, the risk of thyroid carcinoma was not in-
creased and the risk of carcinoma elsewhere was not in-
creased or only marginally increased” [5].
A retrospective study performed by Angusti et al. ana-
lyzed a group of 6647 patients who underwent RT. Thy-
roid cancer was revealed in 10 (0.15%) patients exclusive-
ly with TNG. The time between treatment and cancer di-
agnosis ranged from 2 to 14 years (median 7.5 years). As
no case of thyroid cancer in GD patients has been found,
the authors concluded that RT is safe for GD. For TNG
patients, attention must be focused on the presence of
nodules with suspicious ultrasound pattern [21].
In a paper which described the evolution of ana-
plastic cancer six years after successful RT of toxic ade-
noma, Górowski outlined some hypotheses: cancer may
evolve from paranodular tissue, may be an occult le-
sion with moderate malignancy or increased radiosen-
sitivity, or may evolve de novo [22].
Lucignani notices in his editorial that the reported
thyroid cancer occurrence after RT is not based on evi-
dence-based medicine [9]. However, the proper and
regular follow-up of patients treated with radioiodine
is recommended. Apart from physical examination, the
sequence of follow-up ultrasonography and FNAB ex-
amination is crucial.
Conclusions
Malignant thyroid lesions in patients after RT due to
benign thyroid diseases are seldom detected but not
excluded. Periodical clinical and ultrasonographic eval-
uation is recommended.
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